By contrast, for metastatic castration-sensitive PCa, follow-up targeted genetic studies in matched samples of patients who later displayed progression onto mCRPC have shown that AR is altered in only 2%-6%, suggesting an acquired role for AR amplifications and mutations in mCRPC. This evidence concerns the gene AR and posterior cortical atrophy.